Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Aptevo Reports 79% Remission Rate in TP53-Mutated AML

None

Aptevo Therapeutics Inc. (APVO) reported third-quarter 2026 net loss of $6.5 million, compared with a $7.5 million net loss in the third quarter of 2025. Cash and cash equivalents totaled $8.3 million at September 30, 2026.

The company reported a 79% CR/CRi remission rate among 14 evaluable TP53-mutated acute myeloid leukemia patients receiving mipletamig with venetoclax and azacitidine. Ten of 47 evaluable frontline patients treated with the combination proceeded to allogeneic stem cell transplantation.

  • Thirteen of 14 evaluable TP53-mutated patients, or 93%, experienced clinical benefit.
  • RAINIER Phase 1b dose-optimization completion is targeted by year-end 2026, with regulatory interaction planned for the first half of 2027.
  • August financing generated approximately $4.5 million in gross proceeds and approximately $4.1 million net of issuance costs.
  • Existing and new warrants could provide up to $22.5 million in additional proceeds if exercised.
EARLY ACCESS
Receive APVO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$APVO Hedge Fund Activity

We have seen 3 institutional investors add shares of $APVO stock to their portfolio, and 4 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles